Bleeding Risk Management with Venlafaxine and Valproate Combination

Patient Assessment and Monitoring

The American College of Chest Physicians recommends assessing baseline bleeding risk using the HAS-BLED score, which includes factors such as hypertension, abnormal renal/liver function, stroke, bleeding history, labile INR, elderly, and drugs/alcohol, to identify patients at high risk of bleeding 1
Patients with a HAS-BLED score of 3 or higher require more frequent monitoring and review, according to the American College of Chest Physicians 1
Elderly patients, 75 years or older, have a substantially higher risk of both gastrointestinal and intracranial bleeding, as reported by the American Geriatrics Society 2

The American Heart Association recommends avoiding concurrent use of NSAIDs with venlafaxine and valproate whenever possible, and prescribing proton pump inhibitors for gastroprotection if NSAIDs are required 3
The American Heart Association suggests minimizing the duration of triple therapy, consisting of an anticoagulant and dual antiplatelet therapy, to reduce bleeding complications 3
The National Comprehensive Cancer Network recommends monitoring for thrombocytopenia, defined as a platelet count of less than 50,000/mcL, which represents a relative contraindication to anticoagulation 4

Patients with a history of recent CNS bleeding or intracranial lesions are at high risk for bleeding and have absolute contraindications to anticoagulation, according to the National Comprehensive Cancer Network 4
Active major bleeding requiring more than 2 units of transfusion in 24 hours is an absolute contraindication to anticoagulation, as reported by the National Comprehensive Cancer Network 4
High fall risk or severe platelet dysfunction, resulting from uremia, medications, or dysplastic hematopoiesis, represents relative contraindications to anticoagulation, requiring individualized risk-benefit assessment, according to the National Comprehensive Cancer Network 4